WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 | 3 | 4 |

«VB/06.13 WHO/CDS/EPR/GIP/2006.1 V ORIGINAL: ENGLISH Global pandemic influenza action plan to increase vaccine supply Immunization, Vaccines and ...»

-- [ Page 1 ] --

WHO/IVB/06.13

WHO/CDS/EPR/GIP/2006.1

V

ORIGINAL: ENGLISH

Global pandemic influenza

action plan to increase

vaccine supply

Immunization, Vaccines and Biologicals

Epidemic and Pandemic Alert and Response

WHO/IVB/06.13

WHO/CDS/EPR/GIP/2006.1

V

ORIGINAL: ENGLISH

Global pandemic influenza

action plan to increase

vaccine supply Immunization, Vaccines and Biologicals Epidemic and Pandemic Alert and Response The Department of Immunization, Vaccines and Biologicals and the Department of Epidemic and Pandemic Alert and Response thank the donors whose unspecified financial support has made the production of this publication possible.

This publication was jointly produced by the the Department of Immunization, Vaccines and Biologicals and the Department of Epidemic and Pandemic Alert and Response

Ordering codes:

WHO/IVB/06.13;

WHO/CDS/EPR/GIP/2006.1 Printed: September 2006

This publication is available on the Internet at:

www.who.int/vaccines-documents/

Copies may be requested from:

World Health Organization Department of Immunization, Vaccines and Biologicals CH-1211 Geneva 27, Switzerland

• Fax: + 41 22 791 4227 • Email: vaccines@who.int • © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264;

fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

–  –  –

Acronyms and abbreviations

Executive summary

1. Introduction

2. Overall objectives

3. The present situation and current challenges

4. Major approaches to increasing supplies of pandemic influenza vaccine

4.1 Develop an immunization policy to increase demand for seasonal vaccines.

4.2 Increase influenza vaccine production-capacity

4.3 Promote research and development for new influenza vaccines........ 10

5. Conclusion

References

–  –  –

The objective of the Global Vaccine Action Plan is to increase the supply of a pandemic vaccine and thereby reduce the gap between the potential vaccine demand and supply anticipated during an influenza pandemic.

To mitigate the potential impact of an influenza pandemic, control interventions include two strategies – one, a non-pharmaceutical approach such as social distancing and infection control and the other, a pharmaceutical approach such as the use of influenza vaccines and antivirals for treatment and prophylaxis. In an influenza pandemic most of the world’s population will be highly susceptible to the virus infection and it is conceivable that the virus will spread rapidly. The availability of a pandemic vaccine will be delayed by several months because of the requirements for vaccine formulation and production lead-time. Furthermore, it is probable that insufficient production capacity will restrict global access to the vaccine, at least during the first phase of the pandemic.

Immunization against influenza is considered to be an essential public-health intervention to control both seasonal epidemics and pandemic influenza. Influenza vaccine development and deployment are critical elements of pandemic influenza preparedness. There are marked differences between countries in terms of their respective capacities, priorities and resources to establish a seasonal influenza vaccination policy and programme. The major influenza vaccine producers operate and supply almost exclusively in Australia, Europe, North America and some countries in Asia and Latin America. Most resource-constrained countries do not have the means to access seasonal influenza vaccines and could face this challenge during an influenza pandemic. Planning for appropriate availability of vaccines to manage a pandemic response requires a global perspective and concerted effort, not only in developing a vaccine but also in producing and distributing it.





At the present time, if an influenza pandemic were to occur, the potential vaccine supply would fall several billion doses short of the amount needed to provide protection to the global population.

Countries can assist by: a) developing seasonal influenza vaccination programmes if they can afford to, and b) increasing influenza vaccine coverage in existing programmes. This will provide industry with the clear forecast of demand that is integral to ensuring an incremental increase in seasonal vaccine production-capacity.

This approach, although highly valuable, would be unlikely to raise production capacity to sufficient levels to serve the global population in the foreseeable future.

One important option for the global health community to consider, therefore, is countries’ willingness to pay vaccine manufacturers for unused excess capacity of vaccines.

v Together with the current production challenges, it must be stressed that there are several scientific and technological issues that need to be addressed to facilitate development of effective pandemic vaccine. New influenza candidate vaccines are in the pipeline and clinical trials to evaluate the safety and immunogenicity of candidate H5N1 vaccines are under way. Recently published preliminary results with splitvirus inactivated vaccines show suboptimal immunogenicity. However, more encouraging results have been obtained with whole-virus adjuvanted, inactivated vaccines.

In response to these challenges and in order to develop a Global Vaccine Action Plan for Pandemic Influenza Vaccines, WHO organized a consultation in Geneva on 2–3 May 2006 and invited key stakeholders – from national immunization programmes, national regulatory authorities, vaccine manufacturers and the research community – to participate. The objective of the consultation was to identify and prioritize practical solutions for reducing the anticipated gaps in vaccine supply. The participants drew up an Action Plan with strategies for the short, mid and long term, aiming to increase influenza vaccine production and surge capacity before and during an influenza pandemic. They identified three main approaches: a) an increase in seasonal vaccine use; b) an increase in production capacity; and c) further research and development. The implementation of this plan will require the concerted efforts of countries, industry and the global health community.

Increase in seasonal vaccine use

The first approach relies on countries establishing clear immunization policies to increase the use of seasonal influenza vaccine. This will provide the vaccine industry with a solid demand forecast and stimulate it to increase production capacity. For purposes of the discussion, the participants divided countries into three categories based on their probable demand for seasonal influenza vaccine.

Group 1: Countries that already use seasonal influenza vaccine and that could reach the goal of immunizing 75% of their target population either in the near future or by 2010, as recommended by WHA Resolution 58, 2005.

Group 2: High-income or middle-income countries that currently do not use seasonal influenza vaccine.

Group 3: Low-income countries.

Increased consumption of seasonal influenza vaccine in Group 1 countries could raise demand by 60% above the current annual level of distribution – that is, 350 million annual doses – bringing the annual total demand to 560 million doses.

Group 2 countries need to decide on a policy and conditions required to introduce influenza vaccines into their national immunization schedules in the near future. As an example, the 2006 demand for countries in the Region of the Americas is for approximately 40 million doses, of which 11 million doses of seasonal influenza vaccine will be purchased through the Pan American Health Organization (PAHO) Revolving Fund. This demonstrates that at least a proportion of Group 2 countries will generate demand and thereby promote expansion of the production capacity for influenza vaccines.

vi In Group 3 countries, competing health priorities and the price of trivalent inactive influenza vaccine (currently in the range of US $3–7.00 per dose) is a barrier to the introduction of seasonal influenza vaccination.

Participants identified priority strategies to increase demand for seasonal influenza

vaccine, including:

• development of regional and national plans, and

• resource mobilization to assist countries to purchase both seasonal and pandemic influenza vaccines.

Increase in vaccine production-capacity The second approach concentrates on increasing production capacity for pandemic vaccines, without taking into account the expected demand for seasonal vaccine.

Should there be a pandemic that appears to cause high mortality, there will probably be calls to vaccinate the global population – currently estimated to be 6.7 billion. A pragmatic approach in the short term will be to provide surge-capacity by using antigen-sparing methods; this could result in the availability of more doses.

The participants evaluated various strategies to increase production capacity for

pandemic vaccines and considered the following to be the most promising:

• improving production yields and immunogenicity for vaccines based on H5N1 influenza strains;

• building new production plants in both developing and industrialized countries;

• focusing on further development of adjuvanted vaccines with adjuvants widely used in licensed vaccines;

• expanding the production of live attenuated influenza vaccines (LAIV);

• evaluating the immunogenicity of inactivated whole-virus vaccines;

• evaluating the potential for delivering vaccines by alternative routes – for example, the intradermal route using needle-free delivery devices such as jet injectors.

Further research and development

The third approach builds on research and development efforts being undertaken by the research community – including the vaccine industry – to design more potent and effective vaccines that are: a) capable of inducing protective responses after one dose, and/or b) induce broad spectrum and long-lasting immunity against both seasonal and pandemic influenza strains.

To develop a highly immunogenic and safe vaccine with broader and longer efficacy,

together with more sophisticated tools for vaccine evaluation, the plan focuses on:

–  –  –

In conclusion, the participants identified a number of strategies to bridge the anticipated gap between vaccine demand and supply in the event of a pandemic.

Importantly, none of the strategies will be able to fill the gap in the immediate short term but, if action is taken now, should bear fruit within a future time frame of three to five years. Implementation of the Global Vaccine Action Plan will require substantial funding – preliminary estimates indicate from 3–10 billion US dollars. All stakeholders have important but different and complementary roles to play. Countries that decide to increase coverage with seasonal influenza vaccines will contribute to a sustained augmentation of manufacturing capacity. The international community will be required to shoulder some of the financial burden of: a) improving seasonal influenza vaccine coverage in resource-constrained countries, and b) establishing vaccine production-capacity. This can be done by means of direct investment or technology transfer in developing or middle-income countries. The private sector will also be required to invest in expanding its manufacturing capacities and developing new production technologies.

International organizations, including the World Health Organization, need to take an active role in coordinating and streamlining many of the planned activities. An effective partnership and a commitment to sustaining the effort over 5–10 years are indispensable. Action must start now – this fact cannot be emphasized strongly enough – action must start now if the world is to prepare itself in the shortest possible time for a potential influenza pandemic.

viii 1. Introduction

Although the global burden of seasonal influenza is unknown, it is currently acknowledged to be a burden that spreads across both rich and resource-constrained countries. Pandemic influenza becomes possible when there is an antigenic shift in the haemagglutinin (HA) of an influenza virus to a new type – a type to which virtually the entire human population lacks immunity. Three criteria are needed for

a global influenza pandemic to occur:



Pages:   || 2 | 3 | 4 |


Similar works:

«1 Curriculum Vita John Korstad Feb. 22, 2015 Personal Data: Current Position: Professor of Biology (since Fall 1980) Department of Biology Oral Roberts University 7777 S. Lewis Tulsa, OK 74171 Phone Number: School: (918) 495-6942 Fax: (918) 495-6297 E-mail: jkorstad@oru.edu ORU Faculty Profile: http://webapps.oru.edu/new_php/academics/faculty_profile.php?id=9&k= Education: Undergraduate: California Lutheran University, Thousand Oaks, CA B.A. (Geology) and B.S. (Biology), 1972 Graduate:...»

«The Status of Wild Atlantic Salmon: A River by River Assessment The Status of Wild Atlantic Salmon: A River by River Assessment Table of contents Foreword 1. Introduction 2. Summary of findings 3. Scenarios for the future 4. The biology of Atlantic salmon 5. Threats to salmon populations 5.1 Pollution 5.2 River infrastructure and engineering 5.3 The effect of fisheries on wild Atlantic salmon stocks. 42 5.4 Salmon aquaculture industry 5.5 Stocking and sea-ranching 5.6 Climate change 6. The...»

«New Zealand Data Sheet APO-PREDNISONE Prednisone 1mg, 2.5mg, 5mg and 20mg Tablets Presentation APO-PREDNISONE 1mg tablets are round, white, biconvex, 5.5mm in diameter and identified P over 1 on one side. Each tablet contains 1mg prednisone and typically weighs 80mg. APO-PREDNISONE 2.5mg tablets are round, white, biconvex, 6.0mm in diameter and identified P over 2.5 on one side. Each tablet contains 2.5mg prednisone and typically weighs 87mg. APO-PREDNISONE 5mg tablets are round, white,...»

«STATUS REVIEW OF THE LITTLE BROWN MYOTIS (MYOTIS LUCIFUGUS) AND DETERMINATION THAT IMMEDIATE LISTING UNDER THE ENDANGERED SPECIES ACT IS SCIENTIFICALLY AND LEGALLY WARRANTED *Healthy Little brown myotis in flight *Little brown myotis carcasses in Aelous Cave, VT in 2009 Credit: M. Brock Fenton Credit: Jonathan D. Reichard, Boston University’s CECB Status Review Conducted by: Thomas H. Kunz, Ph.D Jonathan D. Reichard, Ph.D. Boston University’s Center for Ecology and Conservation Biology In...»

«Max Planck Institut für Neurobiologie Direktor: Prof. Dr. Hartmut Wekerle Gene Expression Profiling of Encephalitogenic CD4+ T cells: Identification of Genes Controlling Migration of Effector T cells into the CNS Dissertation der Fakultät für Biologie der Ludwig-Maximilian-Universität München von Vijay Kumar Ulaganathan aus Chennai (Madras) April 2010 Erklärung Hiermit erkläre ich ehrenwörtlich, dass ich die vorliegende Dissertation selbstständig und ohne unerlaubte Hilfe angefertigt...»

«3 He a lt h 2 2 Fire 0 3 0 Re a c t iv it y P e rs o n a l P ro t e c t io n Material Safety Data Sheet Phenol, Liquified, neutralized, for molecular biology MSDS Section 1: Chemical Product and Company Identification Product Name: Phenol, Liquified, neutralized, for Contact Information: molecular biology Sciencelab.com, Inc. 14025 Smith Rd. Catalog Codes: SLP5032 Houston, Texas 77396 CAS#: Mixture. US Sales: 1-800-901-7247 International Sales: 1-281-441-4400 RTECS: Not applicable. Order...»

«Digestive Systems: The Anatomy of Representative Vertebrates Modified from: Biology in the laboratory. 3rd edition. Helms, Helms, Kosinski and Cummings. Biological Investigations: Form, Function, Diversity and Process. 7th Edition. W.D. Dolphin Helms, Helms, Kosinski, Cummings. Biology in the Laboratory, 3rd edition. Freeman Publishing. Harold M. Kaplan and Kathleen A. Jones Southern Illinois University OVERVIEW The digestive system participates in the procurement and metabolism of...»

«1 Human Papillomavirus: Biology and Pathogenesis José Veríssimo Fernandes1 and Thales Allyrio Araújo de Medeiros Fernandes2 1Federal University of Rio Grande do Norte 2University of Rio Grande do Norte State Brazil 1. Introduction The human papillomavirus (HPV) is one of the most common causes of sexually transmitted disease in both men and women around the world, especially in developing countries, where the prevalence of asymptomatic infection varies from 2 to 44%, depending on the...»

«Chemical Check Up An analysis of chemicals in the blood of Members of the European Parliament Where chemicals are found in elevated concentrations in biological fluids such as breast milk, they should be removed from the market immediately. – Royal Commission on Environmental Pollution, 2003 Often the weakest link in determining whether observed adverse effects in humans and/or wildlife are linked to EDCs is the absence of adequate exposure data Data on the magnitude and trends of global...»

«ISSN 2090-4304 J. Basic. Appl. Sci. Res., 2(12)12660-12664, 2012 Journal of Basic and Applied © 2012, TextRoad Publication Scientific Research www.textroad.com Description a Sea Cucumber Species Holothuria atra Jaeger, 1833 from Kish Island Iran (Echinodermata: Holothuroidea) Akram Tehranifard, M.R. Rahimibashar Department of Marine Biology, Lahijan branch.Islamic Azad University Lahijan, Iran ABSTRACT As each new species evolved, the ossicles changed with it, so each species has uniquely...»

«Chapter 2 The Organization of the Gut and the Oral Absorption of Drugs: Anatomical, Biological and Physiological Considerations in Oral Formulation Development Clive G. Wilson Abstract Oral drug delivery remains the mainstay of patient treatment although the candidate drugs of the new millennium are becoming increasingly difficult to formulate for good systemic absorption. The area of oral delivery therefore represents an important area of innovation for pharmaceutical formulation including...»

«Pat r o n e s d e s u c e s i ó n V e g e t a l : im P l i c a n c i a s c o n s e rVa c i ó n lo m a s a t i q u i Pa Pa r a l a de las de d e l de s i e r t o c o s t e r o d e l s u r d e l Pe r ú Patrones de Sucesión Vegetal: Implicancias para la conservación de las Lomas de Atiquipa del Desierto Costero del Sur del Perú diego a. sotomayor melo, Percy JiméneZ milón Departamento Académico de Biología. Universidad Nacional de San Agustín de Arequipa Email:...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.